Literature DB >> 26595139

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Carolina Céspedes-Garro1,2, Ingrid Fricke-Galindo3, María Eugenia G Naranjo1, Fernanda Rodrigues-Soares1,4, Humberto Fariñas1, Fernando de Andrés1, Marisol López-López5, Eva M Peñas-Lledó1, Adrián LLerena1.   

Abstract

INTRODUCTION: Notably differences in CYP2C9 allele frequencies among worldwide populations have been reported, with an interesting low frequency of the CYP2C9*2 allele in Amerindians compared with Admixed and European populations. AREAS COVERED: Literature was searched using the PubMed database and was focused on worldwide original research papers on CYP2C9 alleles and CYP2C9 phenotypes ("predicted" from CYP2C9 genotypes and "measured" metabolic phenotype with a probe drug) among healthy volunteers according to their ethnicity and geographical distribution. Seventy-eight original research articles including a total of 31,978 subjects were identified. EXPERT OPINION: CYP2C9*2 allele is the most frequent in Caucasian populations (average 14%), with the lowest frequencies for Africans (0.46%), East Asians (0.56%) and Native Americans (1.25%), which is in agreement with the hypothesis about the low prevalence in Amerindians. CYP2C9*3 shows the highest frequency among South Asians (11.7%), while CYP2C9*5 (1.56%) and *8 (4.70%) in African Americans. The predicted poor metabolizers (gPMs) were found overall in a low frequency, with the highest frequency detected for South Asians, in accordance with the CYP2C9*3 frequency in these populations. This study shows the worldwide variability in the CYP2C9 allele frequencies across different ethnic and geographic groups. Data about CYP2C9 "measured" metabolic phenotypes is still limited.

Entities:  

Keywords:  CYP2C9; ethnicity; genotype; phenotype

Mesh:

Substances:

Year:  2015        PMID: 26595139     DOI: 10.1517/17425255.2015.1111871

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

1.  Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations.

Authors:  Vanessa Gonzalez-Covarrubias; José Jaime Martínez-Magaña; Regina Coronado-Sosa; Beatriz Villegas-Torres; Alma D Genis-Mendoza; Pablo Canales-Herrerias; Humberto Nicolini; Xavier Soberón
Journal:  Pharm Res       Date:  2016-07-07       Impact factor: 4.200

2.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

3.  Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes.

Authors:  Chang-Keun Cho; Hye-Jung Park; Pureum Kang; Sungmin Moon; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-22       Impact factor: 4.946

Review 4.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.

Authors:  P C D Bank; K E Caudle; J J Swen; R S Gammal; M Whirl-Carrillo; T E Klein; M V Relling; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

Review 5.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

6.  Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population.

Authors:  Fernando de Andrés; Catalina Altamirano-Tinoco; Ronald Ramírez-Roa; Carlos F Montes-Mondragón; Pedro Dorado; Eva M Peñas-Lledó; Adrián LLerena
Journal:  Pharmacogenomics J       Date:  2020-10-06       Impact factor: 3.550

Review 7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

8.  The association of adjusted plasma valproic acid concentration with CYP2C9 gene polymorphism in patients with epilepsy: a systematic review and meta-analysis.

Authors:  Huihui Fang; Xiaojuan Wang; Kelu Hou; Ying Zhang; Shuai Shao; Guijie Zhang; Yufei Feng; Lin Huang
Journal:  Ann Transl Med       Date:  2021-05

9.  Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.

Authors:  Dmitrij Alekseevitch Sychev; Grigorij Nikolaevich Shuev; Salavat Shejhovich Suleymanov; Kristina Anatol'evna Ryzhikova; Karin Badavievich Mirzaev; Elena Anatol'evna Grishina; Natalia Evgenievna Snalina; Zhannet Alimovna Sozaeva; Anton Mikhailovich Grabuzdov; Irina Andreevna Matsneva
Journal:  Pharmgenomics Pers Med       Date:  2017-03-31

10.  Study of the allelic variants CYP2C9*2 and CYP2C9*3 in samples of the Peruvian mestizo population

Authors:  Ángel Tito Alvarado; Ana María Muñoz; Berta Loja; Jessica Michiko Miyasato; Jorge Antonio García; Roberto Andrés Cerro; Luis Abel Quiñones; Nelson Miguel Varela
Journal:  Biomedica       Date:  2019-09-01       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.